RESUMO
BACKGROUND: Cancer is one of the leading causes of death worldwide. Chemotherapy, radiation therapy, and stem cell transplantation were the main cancer treatment approaches for several years but due to their limited effectiveness, there was a constant search for new therapeutic approaches. Cancer immunotherapy that utilizes and enhances the normal capacity of the patient's immune system was used to fight against cancer. Genetically engineered T-cells that express Chimeric Antigen Receptors (CARs) showed remarkable anti-tumor activity against hematologic malignancies and are now being investigated in a variety of solid tumors. The use of this therapy in the last few years has been successful, achieving great success in improving the quality of life and prolonging the survival time of patients with a reduction in remission rates. However, many challenges still need to be resolved in order for this technology to gain widespread adoption. OBJECTIVE: This review summarizes various experimental approaches towards the use of CAR T-- cells in hematologic malignancies and solid tumors. CONCLUSION: Finally, we address the challenges posed by CAR T-cells and discuss strategies for improving the performance of these T-cells in fighting cancers.
